Clinical complete response to serplulimab plus bevacizumab and chemotherapy in MSS/KRAS-mutant metastatic sigmoid colon adenocarcinoma: a case report and literature review.

Abstract excerpt

Mismatched-repair-proficient/microsatellite-stable (pMMR/MSS) metastatic colorectal cancer (mCRC) is typically refractory to immune checkpoint inhibitors. Early randomized data suggest that adding PD-1 blockade to anti-angiogenic therapy and oxaliplatin-based chemotherapy may improve outcomes, but real-world evidence remains limited. A 62-year-old woman presented with advanced sigmoid colon adenocarcinoma and...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Adenocarcinoma
• Share to Antibodies, Monoclonal, Humanized